NYSE: BDX · Medical Instruments & Supplies

Becton, Dickinson (BDX) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Becton, Dickinson (BDX) at $215.74 a share. The stock last closed at $216.47, which puts the model's fair value 0.3% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Becton, Dickinson and Company.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$215.74midpoint of 2,000 simulations
Last close$216.47NYSE: BDX
Gap to fair value-0.3%fair value against price
Model verdictFairly valuedevidence grade: High

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $194.07 to $215.74 (+11.2%). Analysts raised their next-twelve-month EBITDA estimates: most of the move.

What the model makes of itThe price of $216.47 is level with it: Fairly valued, on a high evidence grade.

What's nextNext report on 4 Feb 2027. Options prices imply a move of about 51% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give BDX?

The calibrated range for BDX over 63 trading days is $120.35 to $401.06. It sits around the last close, and its width comes from the volatility that BDX's own options imply (178% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $173.67 to $261.84. In 48% of the simulations the fair value came out above the price the model ran on.

$132.28$336.07
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $215.74. Dashed line: the last close, $216.47.

Faircurve Insights · 14 Nov 2026

Becton, Dickinson and Company (BD) operates globally. It is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology.

Faircurve's model put the fair value at $215.74 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 31 Oct 2026, gave $194.07, so the fair value moved +11.2%. In the model's words, analysts raised their next-twelve-month EBITDA estimates, which is most of the move. The calibrated range over 63 trading days is $172.54 to $256.30, built from the fair value because there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence High. The grade does not say whether the fair value is right.

On quality, the business scores 43 out of 100 against comparable companies, the model's composite of six factors. Stability scores 100, with EBITDA margin downside volatility of 0.4 pts against a peer median of 1.6 pts. Earnings quality scores 97, with FCF / net income of 2.42x against a peer median of 1.13x. The comparable companies are ResMed Inc. (RMD), West Pharmaceutical Services, Inc. (WST), Intuitive Surgical, Inc. (ISRG), Solventum Corporation (SOLV), Baxter International Inc. (BAX), The Cooper Companies, Inc. (COO), Repligen Corporation (RGEN) and Avantor, Inc. (AVTR).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does BDX report earnings, and how has the stock reacted?

Becton, Dickinson's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 41.4% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. BDX's 30 day implied volatility works out to about 51.4% over one month.

How BDX moved around its last 8 earnings reports

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 3.8%.

Report dateTwo session move
5 Nov 2026+1.3%
6 Aug 2026+3.6%
7 May 2026+3.2%
9 Feb 2026+4.0%
6 Nov 2025+0.8%
7 Aug 2025+12.2%
1 May 2025-18.5%
6 Feb 2025-6.2%

How does BDX score on business quality?

Becton, Dickinson's overall quality score is 43 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.04.4%ROIC15.1%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).972.42xFCF / net income1.13x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.18-10.9%Revenue growth, trailing10.1%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.794.1%Net buybacks / market value1.1%
Balance sheetNet debt to EBITDA and interest coverage.183.30xNet debt / EBITDA1.02x
StabilityDownside volatility of the EBITDA margin over the last five years.1000.4 ptsEBITDA margin downside volatility, 5y1.6 pts

How does BDX compare with similar companies?

The companies in medical instruments & supplies closest to Becton, Dickinson in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
RMD ResMed Inc.$238.19$271.74+14.1%Fairly valued
WST West Pharmaceutical Services, Inc.$417.80$372.00-11.0%Fairly valued
ISRG Intuitive Surgical, Inc.$437.75$362.92-17.1%Overvalued
SOLV Solventum Corporation$88.65$88.47-0.2%Fairly valued
BAX Baxter International Inc.$25.54$24.84-2.7%Fairly valued
COO The Cooper Companies, Inc.$61.88$70.88+14.5%Fairly valued
RGEN Repligen Corporation$162.78$152.66-6.2%Fairly valued
AVTR Avantor, Inc.$15.32$20.70+35.1%Undervalued

What the comparable companies' multiples alone would give for BDX, the peer-implied price, is $211.52 a share on this run. The fair value weighs that against the company's own multiple.

All medical instruments & supplies stocks ranked by gap to fair value

Becton, Dickinson at a glance

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology.

Market value
$59.4B
Sector
Healthcare
Industry
Medical Instruments & Supplies
Revenue expected, next twelve months
$19.9B
Consensus revenue growth, next fiscal year
+1.6%
Analysts with estimates
8
Beta to the US market
0.15
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. BDX was not among them.

How the fair value is worked out: the model prices Becton, Dickinson on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 31 Oct 2026 the model's fair value for BDX was $194.07. As of 14 Nov 2026 it is $215.74, a change of +11.2%. Analysts raised their next-twelve-month EBITDA estimates: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Becton, Dickinson's valuation

Is Becton, Dickinson stock undervalued or overvalued?

On Faircurve's model, BDX reads as Fairly valued as of 14 Nov 2026. The model's fair value is $215.74 a share against a last close of $216.47, a gap of -0.3%.

What is BDX's fair value?

$215.74 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $173.67 to $261.84.

What price range does the model give BDX?

$120.35 to $401.06 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Becton, Dickinson report earnings next?

The next report is scheduled for 4 Feb 2027. Companies can move their dates.

How much has BDX moved on past earnings reports?

Across its last 8 reports the median two session move was 3.8%, ignoring direction. The largest was -18.5% around the report of 1 May 2025.

How confident is the model in this valuation?

The model's evidence grade for BDX is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on BDX

The model holds no idea open on BDX today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on BDX with their outcomes. A free account is enough.

Keep reading